Literature DB >> 18769811

[Transient renal failure in a newborn due angiotensin receptor II antagonist use during pregnancy: report of a case].

Jorge Hasbún H1, Enrique Valdés R, Alfredo San Martín O, Jorge Catalán M, Soledad Salinas Q, Mauro Parra C.   

Abstract

Fetal renal structure and function can be altered by medications prescribed to pregnant women. We report a chronic hypertensive pregnant woman treated with losartan before and throughout pregnancy. At 30 weeks the patient was referred to our Fetal Medicine Unit due to absent amniotic fluid with normal uterine artery Doppler and fetal growth. During her hospitalization a new scan was performed showing that both fetal kidneys were enlarged and slightly hyperechogenic and placental and fetal artery Doppler showed signs of hypovolemia or increased resistance to feto-placental blood flow. Ductus venosous was normal. The fetus was delivered after three days by caesarean section at 30+4 weeks of gestation due to abnormal fetal heart rate tracing. Following delivery, the preterm newborn was treated for a transient renal failure characterized by anuria-oliguria and high plasma creatinine levels (from 3.8 mg/dL at day 5 to 0.8 mg/dL at 16 days). At 30 days of age, ultrasound showed kidneys of normal form and size. The adverse effects of Angiotensin II receptor antagonists in fetal nephrogenesis and function are discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18769811     DOI: /S0034-98872008000500012

Source DB:  PubMed          Journal:  Rev Med Chil        ISSN: 0034-9887            Impact factor:   0.553


  2 in total

1.  Maternal olmesartan exposure causing neonatal failure.

Authors:  Antonio Pérez-Iranzo; Ana Nos Ferreres; Aranzazu Jarque Bou
Journal:  BMJ Case Rep       Date:  2017-11-01

Review 2.  Outcomes of 83 fetuses exposed to angiotensin receptor blockers during the second or third trimesters: a literature review.

Authors:  Chisa Shimada; Rina Akaishi; Kazutoshi Cho; Mamoru Morikawa; Yosuke Kaneshi; Takahiro Yamda; Hisanori Minakami
Journal:  Hypertens Res       Date:  2015-02-19       Impact factor: 3.872

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.